Usefulness of S100B protein in neurological disorders

Journal of the Pakistan Medical Association

Volumn 61, Issue 3, 2011, Pages 276-281

  Yardan, Turker ^a   Erenler, Ali Kemal ^a   Baydin, Ahmet ^a   Aydin, Keramettin ^a   Cokluk, Cengiz ^a  

^a ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Brain marker; Neurological disorders; S100B protein

Indexed keywords

BIOCHEMICAL MARKER; PROTEIN S100B;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN CORTEX; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; IMMUNORADIOMETRIC ASSAY; MACROGLIA; MIGRAINE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SCHWANN CELL; SUBARACHNOID HEMORRHAGE; TENSION HEADACHE; TRAUMATIC BRAIN INJURY;

BIOLOGICAL MARKERS; BRAIN INJURIES; HUMANS; NERVE GROWTH FACTORS; NERVOUS SYSTEM DISEASES; S100 PROTEINS;

EID: 79952235847     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60: 614-32.
2. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1: 11-21.
3. Kretsinger RH. Structure and evolution of calcium-modulated proteins. CRC Crit Rev Biochem 1980; 8: 119-74.
4. Sedaghat F, Notopoulos A. S100 protein family and its application in clinical practice. Hippokratia 2008; 12: 198-204.
5. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739-44.
6. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-22.
7. Heizmann CW, Cox JA. New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Biometals 1998; 11: 383-97.
8. Shaw GS, Marlatt NM, Ferguson PL, Barber KR, Bottomley SP. Identification of a dimeric intermediate in the unfolding pathway for the calcium-binding protein S100B. J Mol Biol 2008; 382: 1075-88.
9. Murabayashi M, Minato M, Okuhata Y, Makimoto M, Hosono S, Masaoka N, et al. Kinetics of serum S100B in newborns with intracranial lesions. Pediatr Int 2008; 50: 17-22.
10. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004; 37: 512-8.
11. Drohat AC, Baldisseri DM, Rustandi RR, Weber DJ. Solution structure of calcium-bound rat S100B(betabeta) as determined by nuclear magnetic resonance spectroscopy. Biochemistry 1998; 37: 2729-40.
12. Gonçalves CA, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008; 41: 755-63.
13. Donato R. S100: a multigenic family of calcium-modulated proteins of the EFhand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637-68.
14. Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ. Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991; 88: 3554-8.
15. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007; 85: 1373-80.
16. Gerlach R, Demel G, König HG, Gross U, Prehn JH, Raabe A, et al. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience 2006; 141: 1697-701.
17. Gazzolo D, Monego G, Corvino V, Bruschettini M, Bruschettini P, Zelano G, et al. Human milk contains S100B protein. Biochim Biophys Acta 2003; 1619: 209-12.
18. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007; 8: 2.
19. Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V. Serum S-100B protein in severe head injury.Neurosurgery 1999; 45: 477-83.
20. Nylén K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 2008; 150: 221-7.
21. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, et al. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 2006; 25: 446-53.
22. Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007; 33: 255-60.
23. Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. Resuscitation 2009; 80: 341-5.
24. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma 2005; 22: 645-55.
25. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62: 1130-4.
26. Ishibashi H, Funakoshi Y. Serum S-100B protein levels in left- and righthemisphere strokes. J Clin Neurosci 2008; 15: 520-5.
27. Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, Buchkremer M, Zanella FE, et al. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry 2003; 74: 322-5.
28. Kilminster S, Treasure T, McMillan T, Holt DW. Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery. Stroke 1999; 30: 1869-74.
29. Rosén H, Sunnerhagen KS, Herlitz J, Blomstrand C, Rosengren L. Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. Resuscitation 2001; 49: 183-91.
30. Teepker M, Munk K, Mylius V, Haag A, Möller JC, Oertel WH, et al. Serum concentrations of s100b and NSE in migraine. Headache 2009; 49: 245-52.
31. Papandreou O, Soldatou A, Tsitsika A, Kariyannis C, Papandreou T, Zachariadi A, et al. Serum S100beta protein in children with acute recurrent headache: a potentially useful marker for migraine. Headache 2005; 45: 1313-6.
32. Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry 1988; 51: 1457.
33. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980; 6: 1-9.
34. Weiss N, Sanchez-Peña P, Roche S, Beaudeux JL, Colonne C, Coriat P, et al. Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology 2006; 104: 658-66.
35. Sanchez-Peña P, Pereira AR, Sourour NA, Biondi A, Lejean L, Colonne C, et al. S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit Care Med 2008; 36: 2267-73.
36. Moritz S, Warnat J, Bele S, Graf BM, Woertgen C. The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J Neurosurg Anesthesiol 2010; 22: 21-31.
37. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 1997; 235: 5-8.
38. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 1997; 7: 1069-75.
39. Peña LA, Brecher CW, Marshak DR. Beta-Amyloid regulates gene expression of glial trophic substance S100 beta in C6 glioma and primary astrocyte cultures. Brain Res Mol Brain Res 1995; 34: 118-26.
40. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett 2003; 336: 167-70.
41. Green AJE, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001; 70: 744-8.
42. Nooijen PT, Schoonderwaldt HC, Wevers RA, Hommes OR, Lamers KJ. Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement Geriatr Cogn Disord 1997; 8: 169-73.
43. Schaf DV, Tort AB, Fricke D, Schestatsky P, Portela LV, Souza DO, et al. S100B and NSE serum levels in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 39-43.
44. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, et al. Expression of S-100 protein is related to neuronal damage in MPTPtreated mice. Glia 2003; 42: 307-13.
45. Wilhelm KR, Yanamandra K, Gruden MA, Zamotin V, Malisauskas M, Casaite V, et al. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Eur J Neurol. 2007; 14: 327-34.
46. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-54.
47. Missler U, Wandinger KP, Wiesmann M, Kaps M, Wessel K. Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein. Acta Neurol Scand 1997; 96: 142-4.
48. Hein Née Maier K, Köhler A, Diem R, Sättler MB, Demmer I, Lange P, et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 2008; 436: 72-6.
49. Süssmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003; 353: 57-60.
50. Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neurosci Lett 1998; 240: 171-3.
51. Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, et al. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 2005; 80: 305-13.
52. Qi LY, Xiu MH, Chen da C, Wang F, Kosten TA, Kosten TR, et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009; 462: 113-7.
53. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008; 111: 271-80.
54. Gazzolo D, Frigiola A, Bashir M, Iskander I, Mufeed H, Aboulgar H, et al. Diagnostic accuracy of S100B urinary testing at birth in full-term asphyxiated newborns to predict neonatal death. PLoS One 2009; 4: e4298.
55. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008; 123: 2370-6.
56. Brvar M, Mozina H, Osredkar J, Mozina M, Noc M, Brucan A, et al. S100B protein in carbon monoxide poisoning: a pilot study. Resuscitation 2004; 61: 357-60.
57. Yardan T, Cevik Y, Donderici O, Kavalci C, Yilmaz FM, Yilmaz G, et al. Elevated serum S100B protein and neuron-specific enolase levels in carbon monoxide poisoning. Am J Emerg Med 2009; 27: 838-42.
58. Cakir Z, Aslan S, Umudum Z, Acemoglu H, Akoz A, Turkyilmaz S, et al. S- 100beta and neuron-specific enolase levels in carbon monoxide-related brain injury. Am J Emerg Med 2010; 28: 61-7.
59. Ambrozic J, Bunc M, Osredkar J, Brvar M. S100B protein in benzodiazepine overdose. Emerg Med J 2008; 25: 90-2.